Due to the fact those who have the APOE e4 gene variant seem to have a increased risk of great problems, the FDA recommends being tested for the gene variant before beginning treatment with lecanemab or donanemab. With regards to pharmacological interventions, a few suggestions endorse no pharmacologic intervention. The https://scotty097cob3.mdkblog.com/profile